Janux Therapeutics (JANX) Income towards Parent Company (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Income towards Parent Company data on file, last reported at -$24.4 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$24.4 million, down 3.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.5 million (down 47.25% YoY), and the FY2025 annual result was -$113.6 million, down 64.69% from the prior year.
• Income towards Parent Company advanced to -$24.4 million in Q1 2026 per JANX's latest filing, from -$31.9 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$6.0 million in Q2 2024 and troughed at -$33.9 million in Q2 2025.
• A 5-year average of -$19.3 million and a median of -$17.5 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company plunged 487.13% in 2022, then soared 65.96% in 2024.
• A 5-year view of Income towards Parent Company shows it stood at -$16.1 million in 2022, then gained by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then tumbled by 58.02% to -$31.9 million in 2025, then gained by 23.74% to -$24.4 million in 2026.
• Business Quant data shows JANX's Income towards Parent Company at -$24.4 million in Q1 2026, -$31.9 million in Q4 2025, and -$24.3 million in Q3 2025.